Polymer-Peptide Conjugates for Longer Joint Drug Retention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing drug therapies for intra-articular administration face challenges with rapid clearance from the joint due to hydrodynamic pressures, necessitating frequent injections and increasing the risk of complications and patient burden.

Innovation Solution

Development of biocompatible polymer-peptide conjugates with a molecular weight range of 0.1 MDa to 3 MDa and a peptide-to-polymer molar ratio of at least 5:1, enhancing the intra-articular residence time and therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If intra-articular injection is used to deliver potent drugs directly into the diseased joint, then therapeutic efficacy is improved, but the frequency of administration increases and patient burden increases

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidfrequency of administration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent modifies the molecular weight parameter of the drug conjugate by attaching it to a polymer carrier, changing its physical-chemical properties to achieve prolonged retention in the joint space without altering its therapeutic mechanism

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite structure by conjugating the active drug molecule with a polymer carrier, forming a new material system that combines the therapeutic properties of the drug with the retention properties of the polymer

Inventive Principle:

Principle #40Composite materials

2Reliability

If frequent intra-articular injections are administered to maintain therapeutic levels, then therapeutic efficacy is maintained, but the risk of complications increases

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidrisk of complications

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent performs preliminary action by pre-conjugating the drug to the polymer carrier before administration, creating a formulation designed to release the drug slowly over time, thereby eliminating the need for frequent repeat injections and reducing cumulative complication risks

Inventive Principle:

Principle #10Preliminary action

3Ease of operation

If systemic administration is used to easily deliver drug therapy, then ease of administration is improved, but dangerous side effects occur due to high systemic levels

Engineering Contradiction:

Improveease of administrationVSAvoidsystemic side effects

Core Design Contradiction:

Ease of operationVSObject-generated harmful factors

Solution Approach 1:

The patent introduces the polymer conjugate as an intermediary vehicle that enables local delivery of the drug to the joint space, acting as a mediator between the administration route and the target tissue, thereby achieving both ease of administration and localized action without systemic exposure

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12599663B2Multivalent peptide conjugates for sustained intra-articular treatment of joint inflammation

Publication Date: 2026.04.14 VALITOR INC

AI summary

The present disclosure is directed to peptide-polymer conjugates, and to their use in treating intra-articular diseases or disorders.